A Phase III Superiority Study of Vernakalant vs. Amiodarone in Subjects With Recent Onset Atrial Fibrillation - AVRO

Description:

Currently, ibutilide is the only agent that is Food and Drug Administration (FDA) approved for acute conversion of atrial fibrillation (AF). Other agents that are frequently used, such as amiodarone, are associated with modest efficacy, and frequent side effects. Vernakalant hydrochloride is a newer agent, which showed promising results in a placebo-controlled phase II and III trial. The goal of this trial was to compare the safety and efficacy of vernakalant versus amiodarone in acute co...